Target intelligence / Profile preview

Hes family bHLH transcription factor 7 (HES7)

Target
HES7
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) protein, Orange domain family protein
01

Overview

Hes family bHLH transcription factor 7 (HES7) is a member of the Hairy and Enhancer of Split (HES) family of basic helix-loop-helix (bHLH) transcription factors. HES7 functions primarily as a transcriptional repressor expressed in the presomitic mesoderm, where it plays a pivotal role in the segmentation clock responsible for periodic formation of somites, the structures that later differentiate into the vertebrae and ribs. Its expression is tightly regulated by an intrinsic negative feedback loop, cycling with a period of about two hours, and it is downstream of the Notch signaling pathway, which coordinates cell fate and segmentation timing. Loss-of-function mutations or disturbed expression oscillations in HES7 cause spondylocostal dysostosis and other congenital defects of vertebral and rib patterning, highlighting its essential role in vertebrate embryonic development. It is not currently considered a therapeutic target for small molecules or biologics, nor linked to any approved or experimental drugs.

Other names
Transcription factor HES-7BHLHB37hHes7bHLHb37Class B basic helix-loop-helix protein 37Hairy and enhancer of split 7bHLH factor Hes7SCDO4
02

Biological functions

Transcriptional repressionSomitogenesis (segmentation of presomitic mesoderm into somites)Oscillatory gene expression regulationNegative feedback loop regulationRegulation of Notch signaling pathwayRegulation of cell differentiation and embryonic patterning
03

Disease associations

Spondylocostal dysostosis (particularly type 4, autosomal recessive)Spinal and rib malformations (including abnormal vertebrae, scoliosis)Dextrocardia, situs inversusSpina bifida (including occulta and myelomeningocele)Chiari malformationOther congenital segmental defects of spine and ribs
04

Safety considerations

Mutations can cause severe congenital vertebral and rib malformations, but no therapeutics or biomarker safety concerns presently described (gene-level defects, not druggable target)

Beyond the preview

Go deeper on Hes family bHLH transcription factor 7 (HES7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hes family bHLH transcription factor 7 (HES7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call